Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2012, Article ID 626709, 3 pages
Case Report

Response to Modified Antitubercular Drug Regime and Antiretroviral Therapy in a Case of HIV Infection with Disseminated Tuberculosis with Isoniazid Induced Toxic Epidermal Necrolysis

1Department of Medicine, Silchar Medical College, Silchar 788015, Assam, India
2Silchar Medical College, Silchar 788015, Assam, India

Received 13 October 2012; Accepted 16 November 2012

Academic Editors: K. B. Bamford, X. Vallès, W. I. van der Meijden, and L. Yamuah

Copyright © 2012 Abhijit Swami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO,
  2. Y. Mukadi, J. H. Perriens, M. E. St Louis et al., “Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire,” The Lancet, vol. 342, no. 8864, pp. 143–146, 1993. View at Publisher · View at Google Scholar
  3. L. Goose and C. L. Daley, “Tuberculosis and HIV,” HIV In Site Knowledge Base Chapter, 2003,
  4. World Health Organization, WHO Guidelines for HIV Surveillance Among Tuberculosis Patients: Tb/HIV Working Group of the Global Partnership To Stop Tb and Unaids/Who Working Group on Global HIV/AIDS/STI Surveillance, World Health Organization, Geneva, Switzerland, 2nd edition, 2004.
  5. CDC and WHO, “Guide for HIV/AIDS clinical care, HRSA HIV/AIDS Bureau,” HIV Classification,CDC and WHO Staging Systems, 2011,
  6. A. L. Pozniak, S. Collins, K. M. Coyne et al., “British HIV association guidelines for the treatment of TB/ HIV co-infection,” 2009,
  7. TB/HIV Module for ART Centre Staff, National AIDS Control Organization and Central TB Division Ministry of Health & Family Welfare, Government of India, New Delhi, India, 2010.
  8. “Guidelines for the use ofantiretroviral agents in HIV-1-infected adults and adolescents,”
  9. D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies, “Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 11, pp. 1472–1477, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. B. Marks, K. Dheda, R. Dawson, G. Ainslie, and R. F. Miller, “Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs,” International Journal of STD and AIDS, vol. 20, no. 5, pp. 339–345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lyell, “Toxic epidermal necrolysis: an eruption resembling scalding of the skin,” The British Journal of Dermatology, vol. 68, no. 11, pp. 355–361, 1956. View at Google Scholar · View at Scopus
  12. V. Cohen and M. S. Bronze, “Toxic epidermal necrolysis,”
  13. P. Scheid, G. Kanny, P. Tréchot et al., “Isoniazid-induced bullous skin reaction,” Allergy: European Journal of Allergy and Clinical Immunology, vol. 54, no. 3, pp. 294–297, 1999. View at Google Scholar · View at Scopus
  14. E. Caumes and M. Gentilini, “Fatal toxic epidermal necrolysis in patients with AIDS,” Clinical Infectious Diseases, vol. 21, no. 1, p. 240, 1995. View at Google Scholar · View at Scopus
  15. P. Pitche, T. Mouzou, C. Padonou, and K. Tchangai-Walla, “Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo,” Médecine Tropicale, vol. 65, no. 4, pp. 359–362, 2005. View at Google Scholar · View at Scopus
  16. G. Brambilla, F. Brucato, A. Angrisano, and G. Palmieri, “Treatment of toxic epidermal necrolysis (Ten),” Annals of Burns and Fire Disasters, vol. 15, no. 1, 2002. View at Google Scholar
  17. Guidelines for the management of adverse drug effects of antimycobacterial agents,
  18. WHO, Treatment of Tuberculosis Guidelines, WHO, Geneva, Switzerland, 4th edition, 2010.
  19. WHO, “Antiretroviral therapy for HIV infection in adults and adolescents,”
  20. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,